COMPASS Pathways plc
NASDAQ:CMPSMedical - Care Facilities
+$0.02 today
- Market cap
- $1.15B
- Beta
- 2.51
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$1.63
Volume 2.35M
Average 4.09M
CMPS Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
COMPASS Pathways plcNASDAQ: CMPS
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow grows in line with its trailing trend
Q1 FY2026 financing cash flow of $362.45M rose 158.2% year over year, ahead of the +157.4% change in trailing-twelve-month financing cash flow. Sequentially, it rose 193725.7% from the prior quarter. Over 3 fiscal years it compounded at +413.4% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +158.2% holds above the trailing-twelve-month pace of +157.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 140.71M USD
- Year-over-year change
- +120.5%
- 4-year CAGR
- -2.6%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 140.71M | +120.5% |
| FY2024 | 2024-12-31 | 63.82M | -63.3% |
| FY2023 | 2023-12-31 | 173.83M | +16614.4% |
| FY2022 | 2022-12-31 | 1.04M | -99.3% |
| FY2021 | 2021-12-31 | 156.65M | — |
Financing Cash Flow vs competitors
How CMPS compares with its peers on the latest reported figures
- CMPS's LTM Mar 2026 financing cash flow of $362.11M is the 7th largest of the 11 companies compared; the peer median is $410.89M.
- Its year-over-year change of +157.4% is the 5th highest of 9, against a peer median of +330.0%.
- Over three fiscal years its annual growth of +413.4% compares with a peer median of +89.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $11.32B | — | — | — | |
| LTM Sep 2026 | $1.23B | +505.2% | +306.4% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $1.03B | +3969.6% | +65.4% | — |
| LTM Mar 2026 | $463.02M | +23881.0% | +141.9% | — | |
| LTM Jun 2026 | $425.38M | +1810.7% | -15.2% | 11803.1% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $396.39M | — | +136.2% | — |
| LTM Mar 2026 | $362.11M | +157.4% | +413.4% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $271.31M | +71.7% | +89.7% | 1356.6% |
| LTM Jun 2026 | $51.05M | +154.8% | +82.6% | 4.5% | |
| LTM Jun 2026 | $13.79M | +98.3% | — | 1.4% | |
| LTM Mar 2026 | $2.23M | -101.6% | — | — | |
| Peer median (excluding CMPS) | $410.89M | +330.0% | +89.7% | 680.5% | |
Competitors are the stored peer set for CMPS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.74M) | (91.51M) | (118.46M) | (155.12M) | (287.86M) |
| Depreciation & Amortization | 175K | 330K | 242K | 233K | 216K |
| Deferred Income Tax | 22K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.64M | 13.12M | 17.28M | 19.52M | 13.59M |
| Change in Working Capital | (6.64M) | (30.67M) | 3.48M | 11.72M | (14.28M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (163K) | 2.5M | 864K | 6.59M | 2.03M |
| Other Working Capital | (6.47M) | (33.16M) | 2.62M | 5.13M | (16.32M) |
| Other Non-Cash Items | 1.8M | 3.27M | 86K | 4.46M | 131.1M |
| Operating Cash Flow | (67.75M) | (105.45M) | (97.38M) | (119.19M) | (157.24M) |
| Capital Expenditures | (334K) | (596K) | (66K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 2K | 0 | 0 |
| Investing Cash Flow | (334K) | (596K) | (64K) | 0 | 0 |
| Debt Repayment | 0 | 0 | 29.59M | 0 | 0 |
| Common Stock Issued | 154.79M | 440K | 144.94M | 26.22M | 141.04M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.85M | 600K | (690K) | 37.61M | (328.83K) |
| Financing Cash Flow | 156.65M | 1.04M | 173.83M | 63.82M | 140.71M |
| Effect of Forex Changes | (5.58M) | (24.96M) | 867K | 194K | 1.05M |
| Net Change in Cash | 82.99M | (129.97M) | 77.26M | (55.17M) | (15.48M) |
| Free Cash Flow | (68.08M) | (106.05M) | (97.44M) | (119.19M) | (157.24M) |
COMPASS Pathways plc
NASDAQ:CMPS
Intrinsic Alpha fair value
Locked
Current Price
$8.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.